Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nibec Co., Ltd. (138610:KRX), powered by AI.
Nibec Co., Ltd. is currently trading at ₩23,750. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Nibec Co., Ltd. on Alpha Lenz.
Nibec Co., Ltd.'s P/E ratio is 58.2.
“Nibec Co., Ltd. trades at a P/E of 58.2 (premium valuation) with solid ROE of 11.9%. 3Y revenue CAGR of 14.7% highlights clear growth momentum.”
Ask for details →Nibec Co., Ltd. is a biotechnology company primarily engaged in the research, development, and manufacturing of innovative biomaterials and healthcare solutions. The company's core focus is on the creation of peptide and biomaterial-based technologies tailored for the dental and medical industries. Nibec's groundbreaking research into peptides has led to the development of advanced dental adhesives and bone graft materials that increase the success rate of dental implants and surgeries, thereby impacting the dental healthcare sector significantly. Furthermore, Nibec contributes to the pharmaceutical industry with its development of peptide-based drugs that target various health conditions. The firm is known for its commitment to enhancing life quality through cutting-edge research and application of biomaterials. As part of the broader healthcare and materials sciences market, Nibec plays a vital role in driving innovations that have a lasting impact on medical treatments and patient care, underscoring its importance in the biotechnology and medical sectors.
“Nibec Co., Ltd. trades at a P/E of 58.2 (premium valuation) with solid ROE of 11.9%. 3Y revenue CAGR of 14.7% highlights clear growth momentum.”
Ask for details →Nibec Co., Ltd. (ticker: 138610) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 96 employees. Market cap is $270.0B.
The current price is ₩23,750 with a P/E ratio of 58.16x and P/B of 5.89x.
ROE is 11.89% and operating margin is 15.36%. Annual revenue is $32.7B.